Login / Signup

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation.

Lili Jose SaadeArafat Hussein Tfayli
Published in: Asian Pacific journal of cancer prevention : APJCP (2023)
The administration of Atezolizumab carries a significant risk of developing pneumonitis following chemoradiation therapy for NSCLC. The presence of certain factors and tumor characteristics might affect the chances of having pneumonitis. However due to our small sample size, definitive conclusions could not be drawn.
Keyphrases